Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 6, 2010, Pages 2178-2194

  Lee, Junwon ^a   Lee, Sung Han ^a   Seo, Hee Jeong ^a   Son, Eun Jung ^a   Lee, Suk Ho ^a   Jung, Myung Eun ^a   Lee, MinWoo ^a   Han, Ho Kyun ^a   Kim, Jeongmin ^a   Kang, Jahyo ^b   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

^b Sogang University   (South Korea)

Author keywords

Dapagliflozin; Diabetes; Glucoside; SGLT; Thiadiazole

Indexed keywords

1,3,4 THIADIAZOLE DERIVATIVE; 1,3,4 THIADIAZOLYLMETHYLPHENYL GLUCOSIDE DERIVATIVE; 2 [2 CHLORO 5 [3,5 TRIS(BENZYLOXY) 6 (BENZYLOXYMETHYL)TETRAHYDRO 2H PYRAN 2 YL]BENZYL] 5 (PYRAZIN 2 YL) 1,3,4 THIADIAZOLE; 2 [4 CHLORO 3 [[5 (FURAN 2 YL) 1,3,4 THIADIAZOL 2 YL]METHYL]PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 3 [[5 (THIOPHEN 3 YL) 1,3,4 THIADIAZOL 2 YL]METHYL]PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SYNTHESIS; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; IC 50; MALE; MOUSE; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIABETIC NEPHROPATHIES; DRUG DESIGN; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 77649237649     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.01.073     Document Type: Article

References (27)

1. International Diabetes Federation. Diabetes Atlas. 3rd ed. (2006), International Diabetes Federation, Brussels, Belgium
2. Dwarakanathan A. J. Insur. Med. 38 (2006) 20
3. Mackenzie B., and Loo D.D. J. Biol. Chem. 20 (1996) 32678
4. Wright E.M. Am. J. Physiol. 280 (2001) F10
5. Zhou L., Cryan E.V., D'Andrea M.R., Belkowski S., Conway B.R., and Demarest K.T. J. Cell. Biochem. 90 (2003) 339
6. Evans S., Grasset E., Heyman M., Dumonitier A.M., Beau J.P., and Desjeux J.-F. J. Pediatr. Gastroenterol. Nutr. 4 (1985) 878
7. Moe O.W., Berry C.A., and Rector F.C. In: Brenner B.M., and Rector F.C. (Eds). The Kidney. 5th ed. (2000), WB Saunders Co., Philadelphia 375-415
8. van den Heuvel L.P., Assink K., Willesen M., and Monnens L. Hum. Genet. 111 (2002) 544
9. Ehrenkranz J.R.L., Lewis N.G., Kahn C.R., and Roth J. Diabetes Metab. Res. Rev. 21 (2005) 31
10. Tsujihara K., Hongu M., Saito K., Kawanishi H., Kuriyama K., Matsumoto M., Oku A., Ueta K., Tsuda M., and Saito A. J. Med. Chem. 42 (1999) 5311
11. Fushimi, N.; Ito, F.; Isaji, M. PCT Int. Appl. WO2003011880, 2004.
12. Fujikura, H.; Fushimi, N.; Nishimura, T.; Nakabayashi, T.; Isaji, M. PCT Int. Appl. WO2002053573, 2002.
13. Ellsworth B.A., Meng W., Patel M., Girotra R.N., Wu G., Sher P., Hagan D., Obermeier M., Humphreys W.G., Robertson J.G., Wang A., Han S., Waldron T., Morgan N.N., Whaley J.M., and Washburn W.N. Bioorg. Med. Chem. Lett. 18 (2008) 4770
14. Meng W., Ellsworth B.A., Nirschl A.A., McCann P.J., Patel M., Girotra R.N., Wu G., Sher P.M., Morrison E.P., Biller A.A., Zahler R., Deshpande P.P., Pullockaran A., Hagan D.L., Morgan N., Taylor J.R., Obermeier M.T., Humphreys W.G., Khanna A., Discenza L., Robertson J.G., Wang A., Han S., Wetterau J.R., Janovitz E.B., Flint O.P., Whaley J.M., and Washburn W.N. J. Med. Chem. 51 (2008) 1145
15. Washburn W.N. J. Med. Chem. 52 (2009) 1785
16. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanski, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M. Presented at the 238th American Chemical Society National Meeting and Exposition, Washington, DC, August 16-20, 2009; Medi-151.
17. Johnson & Johnson Pharmaceutical, www.clinicaltrials.gov, NCT00968812, 2009.
18. According to a report from Business Wire on October 02, 2009, dapagliflozin study demonstrated significantly improved glycemic control and weight reduction in type 2 diabetes patients inadequately controlled with metformin.
19. Ellsworth B.A., Doyle A.G., Patel M., Caceres-Cortes J., Meng W., Deshpande P.P., Pullockaran A., and Washburn W.N. Tetrahedron: Asymmetry 14 (2003) 3242
20. Kraus G.A., and Molina M.T. J. Org. Chem. 53 (1998) 752
21. Xie J., Durrant F., and Valery J.-M. J. Org. Chem. 68 (2003) 7896
22. Jung M.E., and Lyster M.A. J. Org. Chem. 42 (1997) 3761
23. Chauvire G., Bouteille B., Enanga B., de Albuquerque C., Croft S.L., Dumas M., and Pri J. J. Med. Chem. 46 (2003) 427
24. Angibeaud P., and Utile J.-P. Synthesis (1991) 737
25. Han S., Hagan D.L., Taylor J.R., Xin L., Meng W., Biller S.A., Wetterau J.R., Washburn W.N., and Whaley J.M. Diabetes 57 (2008) 1723
26. Katsuno K., Fujimori Y., Takemura Y., Hiratochi M., Itoh F., Komatsu Y., Fujikura H., and Isaji M. J. Pharmacol. Exp. Ther. 320 (2007) 323
27. Arakawa K., Ishihara T., Oku A., Nawano M., Ueta K., Kitamura K., Matsumoto M., and Saito A. Br. J. Pharmacol. 132 (2001) 578